CGEM – cullinan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $30.00 price target on the stock.
Form SC 13G/A Cullinan Therapeutics, Filed by: Blue Owl Capital Holdings LP
Form SC 13G/A Cullinan Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SC 13G/A Cullinan Therapeutics, Filed by: VANGUARD GROUP INC
Form SC 13G Cullinan Therapeutics, Filed by: BlackRock, Inc.
Form 4 Cullinan Therapeutics, For: Nov 05 Filed by: Michaelson Jennifer
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.